Ovarian Neoplasms

"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Descriptor ID	D010051
MeSH Number(s)	C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
Concept/Terms	Ovarian Neoplasms Ovarian Neoplasms Neoplasm, Ovarian Ovarian Neoplasm Ovary Neoplasms Neoplasm, Ovary Neoplasms, Ovary Ovary Neoplasm Neoplasms, Ovarian Ovary Cancer Ovary Cancer Cancer, Ovary Cancers, Ovary Ovary Cancers Ovarian Cancer Cancer, Ovarian Cancers, Ovarian Ovarian Cancers Cancer of Ovary Cancer of the Ovary

Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Endocrine Gland Neoplasms [C04.588.322]
Ovarian Neoplasms [C04.588.322.455]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Genital Diseases, Female [C13.351.500]
Adnexal Diseases [C13.351.500.056]
Ovarian Diseases [C13.351.500.056.630]
Ovarian Neoplasms [C13.351.500.056.630.705]
Urogenital Neoplasms [C13.351.937]
Genital Neoplasms, Female [C13.351.937.418]
Ovarian Neoplasms [C13.351.937.418.685]
Endocrine System Diseases [C19]
Endocrine Gland Neoplasms [C19.344]
Ovarian Neoplasms [C19.344.410]
Gonadal Disorders [C19.391]
Ovarian Diseases [C19.391.630]
Ovarian Neoplasms [C19.391.630.705]

Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".

Ovarian Neoplasms
Granulosa Cell Tumor
Hereditary Breast and Ovarian Cancer Syndrome
Luteoma
Meigs Syndrome
Sertoli-Leydig Cell Tumor
Thecoma

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.

Bar chart showing 115 publications over 30 distinct years, with a maximum of 9 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	2	0	2
1997	2	0	2
1998	1	2	3
1999	3	2	5
2001	1	0	1
2002	2	2	4
2003	2	0	2
2004	2	0	2
2005	4	1	5
2006	1	1	2
2007	2	0	2
2008	6	0	6
2009	4	3	7
2010	1	0	1
2011	3	1	4
2012	2	0	2
2013	5	2	7
2014	2	2	4
2015	3	0	3
2016	2	0	2
2017	2	5	7
2018	3	0	3
2019	8	0	8
2020	2	0	2
2021	9	0	9
2022	3	0	3
2023	5	0	5
2024	3	3	6
2025	5	0	5

Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.

Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.

View in: PubMed
Xue T, Liu X, Song C, Fei S, Gu J, Han Y, Xing J, Liu X, Liang F, Thompson PR, Zhang X. Citrullination of AKT2 Catalyzed by PAD1 Facilitates the Maintenance of Stemness Characteristics of Ovarian Cancer Stem-Like Cells in Ovarian Cancer. Adv Sci (Weinh). 2025 Oct; 12(39):e01014.

View in: PubMed
You B, Anderson C, Cecere SC, Carrot A, Myers T, Heitz F, Sharma S, Sel?ukbiricik F, Aghajanian C, Fernebro J, Blank S, Laudani ME, Thaker PH, Yunokawa M, Willmott L, Lisyanskaya A, Hegg R, He Y, Landen C, Lin YG, Alarc?n J, Moore KN. Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial. Gynecol Oncol. 2025 Jun; 197:66-73.

View in: PubMed
Herzog TJ, Liao JB, Finkelstein K, Willmott L, Duan W, Moroney JW, Buscema J, Campbell-Simms K, Yue Y, Zweizig S, Liu J, Wang X, Zang RY, Yin R, O'Malley DM, Wu L. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.

View in: PubMed
Goh KY, Tham SC, Cheng TY, Nadarajah R, Goh RCH, Wong SL, Ho TH, Chew GK, Tan AWK, Rajesh H, Chua HL, Yong TT, Yu SL, Kang JM, Lau KW, Tay AZE, Mantoo S, Busmanis I, Chew SH, Lim TYK, Wong WL, Ng QJ, Wang J, Tay SK, Cheok CF, Lim DW, Lim EH. Cell Migration in Endometriosis Responds to Omentum-Derived Molecular Cues Similar to Ovarian Cancer. Int J Mol Sci. 2025 Feb 20; 26(5).

View in: PubMed
MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 Dec; 144:103775.

View in: PubMed
O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRa-high platinum-sensitive ovarian cancer. Future Oncol. 2024; 20(32):2423-2436.

View in: PubMed
Polan RM, Ali-Fehmi R, Grace AK, Mattei LH, Tanner EJ, Morris RT. Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations. Gynecol Oncol. 2024 Oct; 189:37-40.

View in: PubMed
Mattei LH. The Maternal Crossroad. N Engl J Med. 2024 06 20; 390(23):2139-2141.

View in: PubMed
Mishra AK, Ye T, Banday S, Thakare RP, Su CT, Pham NNH, Ali A, Kulshreshtha A, Chowdhury SR, Simone TM, Hu K, Zhu LJ, Eisenhaber B, Deibler SK, Simin K, Thompson PR, Kelliher MA, Eisenhaber F, Malonia SK, Green MR. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. Cell Rep. 2024 04 23; 43(4):114041.

View in: PubMed

People

Explore

Similar Concepts

Top Journals